← All trials
NCT06340490
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 15, 2024
- Primary completion
- Dec 31, 2026
- Completion date
- Dec 31, 2027
- First posted
- Apr 1, 2024
- Last posted
- Apr 1, 2024
- Enrollment
- 24
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of ChinaLead sponsor
- Jiao Tong UniversityCollaborator
- Changhai HospitalCollaborator
- Jiao Tong UniversityOfficial
- Nanjing UniversityCollaborator
- Peking UniversityCollaborator
- Peking UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.